Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials
- Conditions
- Poor Ovarian Reserve
- Interventions
- Drug: 4 IU of recombinant GH (Somatotropin )
- Registration Number
- NCT05602090
- Lead Sponsor
- Beni-Suef University
- Brief Summary
Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor ovarian Reserve Patients
- Detailed Description
To study the effect of growth hormone as adjuvant treatment on the outcomes of ICSI trials in poor ovarian reserve patients.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 120
According to Bologna criteria (((at least two )))of the following features must be present:
-
Advanced maternal age (40years).
-
A previous poor ovarian response with 3 oocytes retrieved after conventional stimulation
-
An abnormal ovarian reserve test (ORT)
- antral follicle count (AFC)<7 or
- anti-Müllerian hormone (AMH)<1.1ng/ml.
- Any known contraindications to the approved fertility drugs.
- Any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment)
4- Hydrosalpinx 5- Uterine malformations or abnormal uterine cavity. 6- Basal FSH more than 17 IU. 7- Abnormal karyotyping 8- Partner with severe male factor 9- Uncontrolled endocrinopathies: DM, hyperthyroidism, hypothyroidism.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Growth Hormone adjuvant treatment 4 IU of recombinant GH (Somatotropin ) Growth hormone in this trial will use 4 IU of recombinant GH (Somatotropin, ) by day after day subcutaneous injection for 6 weeks before starting cycle. And on start day of induction ( Day 2 to 3) until the day of the human chorionic gonadotropin (hCG) trigger.
- Primary Outcome Measures
Name Time Method pregnancy rate ICSI trial (1month) HCG positive
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Beni-suef university
🇪🇬Banī Suwayf, Beni Suef, Egypt